Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P15056
UPID:
BRAF_HUMAN
Alternative names:
Proto-oncogene B-Raf; p94; v-Raf murine sarcoma viral oncogene homolog B1
Alternative UPACC:
P15056; A4D1T4; B6HY61; B6HY62; B6HY63; B6HY64; B6HY65; B6HY66; Q13878; Q3MIN6; Q9UDP8; Q9Y6T3
Background:
Serine/threonine-protein kinase B-raf, also known as Proto-oncogene B-Raf, plays a pivotal role in mediating cell growth and division signals. It activates the MAP kinase signal transduction pathway, crucial for cell proliferation, differentiation, and survival. Its involvement in phosphorylating MAP2K1 and PFKFB2 underscores its significance in cellular signaling.
Therapeutic significance:
B-Raf's aberrant activity is linked to various cancers, including colorectal, lung, and non-Hodgkin lymphoma, highlighting its potential as a therapeutic target. Understanding B-Raf's role could pave the way for innovative treatments, particularly in cancers where it's implicated.